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ABSTRACT  
Background: Preliminary evidence suggests that peak exercise oxygen pulse (peO2p) - peak oxygen 
uptake/heart rate, a variable obtained during maximal cardiopulmonary exercise testing and a surrogate of 
stroke volume, is a predictor of mortality. We aimed to assess the associations of peO2p with sudden 
cardiac death (SCD), fatal coronary heart disease (CHD) and cardiovascular disease (CVD), and all-cause 
mortality.  
Design: A prospective study 
Methods: Peak exercise O2 pulse was assessed in a maximal cycling testing at baseline in 2,227 middle-
aged men of the Kuopio Ischemic Heart Disease cohort study using expired gas variables and 
electrocardiograms. Relative peO2p was obtained by dividing the absolute value by body weight.  
Results: During a median follow-up of 26.1 years 1,097 died; 220 SCDs, 336 fatal CHDs and 505 fatal 
CVDs. Relative peO2p (mean 19.5 (4.1) mL per beat-1·kg-1·102) was approximately linearly associated 
with each outcome. Comparing extreme quartiles of relative peO2p, hazard ratios (HRs) (95% CIs) for 
SCD, fatal CHD and CVD, and all-cause mortality on adjustment for cardiovascular risk factors were 
0.55 (0.36-0.83), 0.58 (0.42-0.81), 0.60 (0.46-0.79), and 0.59 (0.49-0.70) respectively (P<0.001 for all). 
The HRs were unchanged on further adjustment for C-reactive protein and use of beta-blockers. Addition 
of relative peO2p to a CVD mortality risk prediction model significantly improved risk discrimination (C-
index change=0.0112; P=0.030).  
Conclusion: Relative peO2p measured during maximal exercise was linearly and inversely associated 
with fatal cardiovascular and all-cause mortality events in middle-aged men. Additionally, relative peO2p 
provided significant improvement in CVD mortality risk assessment beyond conventional risk factors. 
 
Keywords: peak exercise oxygen pulse; cardiopulmonary exercise testing; risk prediction; sudden cardiac 
death; cardiovascular diseases; all-cause mortality 
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Introduction 
Cardiorespiratory or aerobic fitness, as measured by peak oxygen uptake (VO2), has been one of the most 
widely examined CPX variables, particularly as it relates to functional capacity and human performance.1, 
2 In previous cohort studies, peak VO2 has been shown to be inversely and independently associated with 
incident cardiovascular disease (CVD) events, cardiovascular and total mortality.3-7 Evidence also 
suggests that peak VO2 adds additional prognostic value beyond established risk factors in predicting 
vascular disease and mortality risk.3, 8, 9  
Stroke volume response is one of the most important measures of cardiac performance during 
exercise.10, 11 Exercise oxygen (O2) pulse, a surrogate for stroke volume (SV), has emerged as an 
important variable which is obtained during cardiopulmonary exercise testing (CPX). Peak exercise 
oxygen pulse (peO2p) is expressed as O2 consumed per heart beat at maximal CPX and it is related to the 
risk of cardiovascular events.12  
There is evidence to show that a high peO2p is inversely related to all-cause mortality.10, 13 However, 
data on the value of utilizing peO2p as a risk assessment tool for serious and specific adverse events such 
as sudden cardiac death (SCD) and fatal coronary heart disease (CHD) are lacking. Although in the 
literature, peO2p is often expressed by its absolute value (i.e. mL/beat), its magnitude is obviously related 
to body dimensions. Thus ideally, similarly to peak VO2, it should be expressed in relative form, that is, 
by dividing its absolute value by body weight.11 Given the relative ease at which this exercise testing 
variable can be assessed noninvasively using expired gases analysis, it will be clinically relevant to know 
if peO2p is a significant risk marker for fatal cardiovascular events and if it adds additional information 
beyond well-established cardiovascular risk factors. Our primary aim was to assess the nature and 
magnitude of the associations of relative peO2p with the risk of SCD, fatal CHD and CVD events, and all-
cause mortality using a population-based prospective cohort Finnish study . A secondary aim was to 
evaluate whether addition of relative peO2p measurements to conventional cardiovascular risk factors 
could improve the prediction of CVD mortality.  
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Methods  
Study population 
The STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines for 
reporting observational studies in epidemiology were used in this study (Appendix).14 Data analysis was 
undertaken in participants of the Finnish Kuopio Ischemic Heart Disease (KIHD) risk factor study, a 
prospective general population-based cohort study which aimed to study related risk factors for 
atherosclerotic CVD and other related chronic disease outcomes to aerobic performance. Detailed 
description of the study design, objectives, and sampling strategy has been previously reported.15 The 
KIHD cohort was recruited from a representative sample of 3,433 men aged 42-61 years who were living 
in the city of Kuopio (Finland) and its surrounding communities. Of this number, 3,235 men were found 
to be eligible for inclusion and  2,682 (82.9%) volunteered to participate in the study. Baseline exa-
minations were performed between March 1984 and December 1989. For the current analysis, 2,227 men 
with complete information on relative peO2p, relevant covariates, and fatal outcomes were included. The 
medical ethics committee of the University of Eastern Finland approved the study protocol which was 
conducted in accordance with the Declaration of Helsinki. All study participants provided written 
informed consent.  
 
Assessment of peak oxygen pulse 
All participants underwent a morning symptom-limited cycling exercise testing.16 with breath-by-
breath respiratory gas analysis (Medical Graphics, US). Peak VO2 was assessed as previously described5, 
16 and peO2p was calculated by dividing the measured peak VO2 by the maximum exercise heart rate, 
obtained from electrocardiogram, and was expressed in mL/beat. To remove the influence of body weight 
on the magnitude of peO2p, values of peO2p were then divided by weight in kilograms to yield relative 
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peO2p. All results were multiplied by 100 for easier readability, as previously described.11, 17 To ensure 
safety, all tests were supervised by experienced physician and nurse.  
 
Assessment of covariates 
Baseline data were obtained by history, questionnaire administration, physical examinations, and 
measurements as detailed elsewhere.18, 19 Fasting cholesterol contents of serum lipoprotein fractions, 
triglycerides, plasma glucose, and serum high sensitivity C-reactive protein (hsCRP) were obtained from 
analysis of blood samples. Smoking, prevalent diseases, and regular and current use of medications were 
assessed by standardized self-administered questionnaires.18 Alcohol consumption was assessed using the 
Nordic Alcohol Consumption Inventory. Resting blood pressure was measured before the CPX with a 
random-zero sphygmomanometer. History of CHD was based on a previous myocardial infarction, angina 
pectoris, use of nitroglycerin for chest pain once a week or more frequently or typical chest pain. The 
amount of physical activity was assessed from a 12-month physical activity history modified from the 
Minnesota Leisure-Time Physical Activity Questionnaire,20 and expressed in kJ/day.16  
 
Ascertainment of outcomes 
All SCD, fatal CHD and CVD, and all-cause mortality events were ascertained from hospital documents, 
discharge lists, death certificates, informant interviews, health practitioner questionnaires, study 
electrocardiograms, medico-legal reports, and vital statistics offices from study enrollment through to the 
end of 2014. The diagnostic classification of SCDs was based on symptoms, electrocardiographic 
findings, cardiac enzyme elevations, autopsy findings, and history of CHD plus clinical findings and 
information from hospital and paramedic staff, details of which have been previously described.5, 21, 22 
CVD deaths were coded using the Tenth International Classification of Diseases codes. Documents were 
cross-checked in detail by two physicians.  
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Statistical analysis 
Baseline characteristics of study participants were summarized using descriptive statistics (i.e., means, 
medians, and percentages). Cross-sectional associations of relative peO2p with risk markers were assessed 
by calculating age-adjusted partial correlation coefficients. Hazard ratios (HRs) with 95% confidence 
intervals (CIs) for SCD, fatal CHD and CVD events, and all-cause mortality were calculated using Cox 
proportional hazard models after confirmation of the proportionality-hazards assumption using 
Schoenfeld residuals. The shape of the association between relative peO2p and each fatal outcome was 
characterized by calculating the HRs within quartiles of baseline relative peO2p and plotting these against 
the mean values of relative peO2p within each quartile using floating variances as described previously.23, 
24 We modelled our exposure as both continuous (per standard deviation, SD increase) and categorical 
(quartiles) variables. Hazard ratios were progressively adjusted for (i) age (Model 1); (ii) systolic blood 
pressure (SBP), total cholesterol, high-density lipoprotein cholesterol (HDL-C), smoking status, alcohol 
consumption, prevalent CHD, history of diabetes mellitus, and amount of physical activity (Model 2); and 
(iii) hsCRP and use of beta-blockers (Model 3). Subgroup analyses were performed using interaction tests 
to assess statistical evidence of effect modification by relevant clinical characteristics. To assess whether 
adding information on relative peO2p to documented established risk factors is associated with 
improvement in prediction of CVD mortality risk, we calculated measures of discrimination for censored 
time-to-event data (Harrell’s C-index25) and reclassification.26, 27 To investigate the change in C-index, we 
added relative peO2p to a CVD mortality risk prediction model (i.e., age, SBP, history of diabetes, total 
cholesterol, HDL-C, and smoking). Reclassification analysis was restricted to the first 10 years and was 
assessed using the net-reclassification-improvement (NRI).26, 27 Given that we used CVD mortality as the 
outcome, we followed European guidelines28 to determine clinically meaningful risk categories. 
Reclassification analyses was based on predicted 10-year CVD mortality risk categories of low (<1%), 
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intermediate (1 to <5%), and high (≥5%) risk. All statistical analyses were conducted using Stata version 
14 (Stata Corp, College Station, US). 
 
Results 
Baseline characteristics and correlates of relative peO2p 
The baseline mean (standard deviation) age and relative peO2p were 53 (5) years and 19.5 (4.1) mL per 
beat-1.kg-1.102, respectively (Table 1). Relative peO2p was weakly-to-moderately inversely correlated 
with age, alcohol consumption, physical measurements (body mass index, blood pressure, and resting 
heart rate), lipids (total cholesterol and triglycerides), fasting plasma glucose, and hsCRP. There was a 
relatively weak positive correlation of relative peO2p with regular physical activity (r = 0.08), and HDL-C 
(r = 0.22) (Table 1). Values of relative peO2p were lower in the presence of history of CHD, 
hypertension, diabetes, current smoking and use of antihypertensives.  
 
Relative peO2p and mortality 
During a median (interquartile range) follow-up of 26.1 (19.1-28.1) years 1,097 subjects died (49.2% of 
study’s sample), with a total of 220 SCDs, 336 fatal CHDs, and 505 fatal CVDs. In analyses adjusted for 
several established risk factors (age, SBP, total cholesterol, HDL-C, smoking status, alcohol 
consumption, prevalent CHD, history of diabetes mellitus, and physical activity), relative peO2p was 
approximately linearly and inversely associated with SCD, fatal CHD, fatal CVD, and all-cause mortality 
(P<0.001) (Figure 1). Table 2 summarizes the HRs (95% CIs) of relative peO2p with each fatal outcome 
assessed. In age-adjusted analysis, the HRs (95% CIs) for SCD, fatal CHD, fatal CVD, and all-cause 
mortality per 1 SD increase in relative peO2p were 0.63 (0.54-0.73), 0.63 (0.56-0.71), 0.66 (0.60-0.73), 
and 0.73 (0.68-0.78) (P<0.001), respectively. The associations (HRs) remained consistent and significant 
after adjustment for several established cardiovascular risk factors plus hsCRP and use of beta-blockers; 
0.76 (0.65-0.89), 0.75 (0.66-0.86), 0.77 (0.70-0.86), and 0.80 (0.74-0.86), respectively. Alternatively, 
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comparing the top versus bottom quartile of relative peO2p, the age-adjusted HRs (95% CIs) for SCD, 
fatal CHD, fatal CVD, and all-cause mortality were 0.35 (0.24-0.53), 0.39 (0.28-0.53), 0.42 (0.33-0.54), 
and 0.49 (0.41-0.58) (P<0.001), respectively, and also significant after adjustment for several established 
cardiovascular risk factors with hsCRP and use of beta-blockers, the corresponding hazard ratios were 
0.54 (0.36-0.82), 0.57 (0.41-0.80), 0.61 (0.47-0.80), and 0.61 (0.51-0.73), respectively (Table 2). The 
associations were generally not modified by several clinically relevant characteristics (Figures 2 and 3), 
except for suggestion of effect modification by history of CHD for the association of relative peO2p with 
SCD. Though the associations were in the same direction, stronger protective associations were observed 
in presence of a history of CHD. Peak O2p was associated with SCD, fatal CHD, fatal CVD and all-cause 
mortality among men who were not using b-blockers as well as among those were using beta-blockers as 
shown in Figure 2 and 3 and this relationship was not modified by the use of beta-blockers.  
 
Relative peO2p and CVD mortality risk prediction 
A CVD mortality risk prediction model containing established risk factors yielded a C-index of 0.7009 
(95% CI: 0.6784-0.7234). After addition of information on relative peO2p, C-index changed to 0.7121 
(95% CI: 0.6899-0.7344), representing a significant increase of 0.0112 (95% CI: 0.0011 to 0.0214; 
P=0.030). However, there was no improvement in the classification of participants into predicted 10-year 
CVD mortality risk categories (NRI: 4.18%, -3.24 to 11.61%; P=0.269).  
In an approach to compare the predictive ability of relative peO2p with peak VO2, which has been 
consistently shown to improve CVD risk prediction above that of traditional cardiovascular risk factors,3, 
8, 29 peak VO2 measurements was added to the CVD mortality prognostic model. There was a C-index 
change of 0.0348 (95% CI: 0199 to 0.0497; P < 0.001) and it yielded a NRI of 16.40% (8.21 to 24.59%; P 
< 0.001) for the predicted 10-year CVD mortality risk categories.  
Furthermore, in a prediction model containing established risk factors plus peak VO2, the C-index 
change was 0.0028 (95% CI: -0.0011 to 0.0068; P=0.161) on addition of information on relative peO2p 
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and NRI was 1.15% (-3.17 to 5.48%; P=0.601). 
 
Discussion 
In this population-based prospective cohort study of apparently healthy Finnish men with a median 
follow-up period of over 25 years, we found approximately significant, linear and inverse associations of 
relative peO2p with distinct fatal cardiovascular and all-cause mortality outcomes. The associations were 
independent of several established and emerging cardiovascular risk factors. The magnitude and 
directions of the associations were generally consistent across several clinically relevant subgroups 
including the use of beta-blockers (yes vs. no), except by the possible effect modification by history of 
CHD on relative peO2p and SCD association. The stronger inverse association between relative peO2p 
and SCD risk in men with a prevalent history of CHD may corroborate existing evidence that exercise 
training has more beneficial effects on adverse outcomes in individuals with pre-existing cardiometabolic 
disease.30  Furthermore, findings from the assessments of improvements in risk discrimination indicate 
that relative peO2p provides a significant improvement in CVD mortality risk prediction but not beyond 
that provided by established cardiovascular risk factors and peak VO2. Further analyses showed that the 
improvement provided by peak VO2 assessment in prediction of CVD mortality risk was better than that 
of relative peO2p, which further confirms the superiority of peak VO2 as a prognostic tool. 
The concept of oxygen pulse is more than 100 years old.31 Notwithstanding, studies on the 
associations of peO2p with cardiovascular and mortality outcomes are limited and have been based in 
populations with smaller sample sizes or with pre-existing disease and have rarely taken in account the 
body weight, i.e. the relative peO2p. In a French study that compared the long-term prognostic value of 
peO2p and peak VO2 in 178 patients with chronic heart failure, peO2p was found to have a lower 
prognostic value for survival compared with peak VO2,12 however, in a larger sample of 998 heart failure 
patients32, the age-predicted peO2p (an indirect way to adjust peO2p per body weight) has complemented 
peak O2 in the prediction of risk for mortality, while Lavie et al33 studied 209 patients with mild-to-
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moderate heart failure and found that peO2p/lean body mass outperforms peak O2. These apparently 
contradictory findings may be explained by different ways to analyze peO2p data, either as an absolute 
value or in same way related to body weight or lean body mass. Our data have shown that relative peO2p 
is independently associated with several long-term cause-specific cardiovascular mortality outcomes as 
well as all-cause mortality in a general middle-aged population. Additionally, we showed that relative 
peO2p provided prognostic value for CVD mortality beyond established risk factors, although, there was 
no significant improvement beyond that of peak VO2. Considering that these two CPX variables are 
mathematically related and that both improve with exercise training,34 these relatively similar results are 
not surprising. Indeed, if relative peO2p or peak VO2 will be a better prognostic indicator may vary 
according to the characteristics of subjects being studied and the outcomes that are being examined.35, 36 
Considering the easiness in determining relative peO2p from expired gas analysis, it seems quite logical to 
include this result in CPX reports.   
There is growing evidence on the clinical usefulness of CPX variables as supported by several 
guidelines.37, 38 Notwithstanding, incorporation of these CPX variables in clinical practice is still limited. 
Currently, peak VO2, VO2 at ventilatory/anaerobic threshold, and ventilatory efficiency (i.e., minute 
ventilation/carbon dioxide production (VE/VCO2) relationship are the only three CPX variables that have 
been consistently proven to show prognostic significance .39 Peak exercise oxygen pulse, is gaining 
attention as a clinically useful variable and can easily be obtained during CPX and computed as the ratio 
of maximum values of VO2 and heart rate. Additionally, interpretation of exercise  oxygen pulse curves 
could also be clinically relevant, since abnormal and flat oxygen pulse curves during CPX have been 
shown to reflect left ventricular dysfunction40 and myocardial ischemia41, 42 or fibrosis43.  The prognostic 
utility of the peO2p curves deserves further study.  
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Strengths and limitations 
We have reported the first prospective evaluation of the associations of relative peO2p, i.e. peO2p/body 
weight, with the risk of major fatal cardiovascular events and all-cause mortality outcomes in a general 
population setting.    The KIHD cohort was characterised by a high participation rate and no losses to 
follow-up were recorded, which minimised potential selection bias. Additionally, outcomes were 
confirmed and validated.5, 8 We have utilized comprehensive analysis which included adjustment for 
several lifestyle and biological markers, assessment of the dose-response relationships, subgroup 
analyses, and risk prediction analyses. Oxygen pulse is an indicator of SV response to exercise that might 
be influenced by body dimensions and heart size,44 and adjustments for body size and/or weight should be 
ideally included in studies on peO2p, especially if data from male and female subjects are to be compared 
in different populations.  The lack of control for confounding variables such as body weight might have 
limited the interpretation of previous reports.10, 42 In our analyses, we used a relative peO2p which took 
into account body weight, thus strengthening the validity of the results.  
When interpreting the results, some limitations should be considered. The KIHD study included 
middle-aged Caucasian men from eastern Finland, so extrapolation to other populations and age groups, 
and particularly for women, might not be valid and more research is needed in this regard. Though we 
adjusted for a comprehensive panel of covariates, residual confounding remains a potential alternative 
explanation for our findings, due to the observational design of the study. According to the Fick equation, 
O2 pulse equals the product of SV and arterio-venous oxygen difference, whiles O2 pulse tends to exhibit 
a quasi-linear increase throughout maximal exercise.11 We have previously shown that left ventricular 
diastolic and systolic diameter are directly associated with peO2p.10 Even though direct measurements of 
SV were not available in the current study, there is convincing evidence that O2 pulse correlates well with 
direct measurements of SV during submaximal and maximal exercise in healthy and unhealthy subjects of 
different age groups.40, 44-46   
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In conclusion, the findings of this large prospective cohort study in middle-aged Finnish men with 
long-term follow-up indicate strong linear and inverse associations of relative peO2p with fatal 
cardiovascular and all-cause mortality events. Additionally, the incorporation of relative peO2p during a 
maximal cycling CPX provides significant improvement in CVD mortality risk assessment beyond 
several conventional risk factors. 
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Table 1. Baseline participant characteristics and correlates of relative peak exercise oxygen pulse 
 
  
Mean (SD), median 
(IQR), or n (%) 
Partial correlation 
r (95% CI)a 
Absolute difference (95% CI) in values 
of relative peO2p per 1 SD higher or 
compared to reference category of 
correlateb 
Peak exercise oxygen pulse (mL/beats) 15.5 (3.4) - - 
Relative peO2p (mL/beats/kg) 19.5 (4.1) - - 
    
Questionnaire/Prevalent conditions    
Age at survey (years) 53 (5) -0.15 (-0.19, -0.11)*** -0.62% (-0.79, -0.46)*** 
Alcohol consumption (g/week) 74.3 (122.2) -0.10 (-0.14, -0.06)*** -0.40% (-0.56, -0.23) 
History of diabetes    
    No 2,149 (96.5) - Ref 
    Yes 78 (3.5) - -1.92% (-2.83, -1.00)*** 
Smoking status    
    Other 1,530 (68.7) - Ref 
    Current 697 (31.3) - -0.64% (-1.00, -0.28)** 
History of hypertension    
    No 1,568 (70.4) - Ref 
    Yes 659 (29.6) - -0.68% (-1.05, -0.31)** 
History of CHD    
    No 1,701 (76.4) - Ref 
    Yes 526 (23.6) - -1.38% (-1.78, -0.98)*** 
Use of anti-hypertensives    
    No 1,762 (79.1) - Ref 
    Yes 465 (20.9) - -0.67% (-1.09, -0.26)* 
Use of beta-blockers    
    No 1,847 (82.9) - Ref 
    Yes 380 (17.1) - -0.13% (-0.59, 0.32) 
    
Physical measurements    
BMI (kg/m2) 26.9 (3.4) -0.33 (-0.37, -0.29)*** -1.33% (-1.49, -1.17)*** 
Weight (kg) 80.3 (11.8) -0.31 (-0.34, -0.27)*** -1.24% (-1.40, -1.08)*** 
SBP (mmHg) 134 (17) -0.17 (-0.21, -0.13)*** -0.68% (-0.85, -0.52)*** 
DBP (mmHg) 89 (10) -0.19 (-0.23, -0.15)*** -0.77% (-0.93, -0.60)*** 
Physical activity (kj/day) 1,545 (1,408) 0.08 (0.04, 0.12)** 0.33% (0.17, 0.50)*** 
Heart rate (beats/min) 62.4 (10.8) -0.38 (-0.42, -0.34)*** -1.54% (-1.71, -1.38)*** 
    
Lipid markers    
Total cholesterol (mmol/l) 5.91 (1.07) -0.05 (-0.10, -0.01)* -0.22% (-0.39, -0.05)* 
HDL-C (mmol/l) 1.29 (0.30) 0.22 (0.18, 0.26)*** 0.89% (0.72, 1.05)*** 
Triglycerides (mmol/l) 1.09 (0.79-1.54) -0.25 (-0.29, -0.21)*** -1.02% (-1.18, -0.85)*** 
    
Metabolic, renal markers, and 
inflammatory markers 
   
Fasting plasma glucose (mmol/l) 5.33 (1.20) -0.17 (-0.21, -0.12)*** -0.67% (-0.83, -0.50)*** 
Serum creatinine (µmol/1) 89.7 (21.7) -0.02 (-0.07, 0.02) -0.09% (-0.27, 0.08) 
Estimated GFR (ml/min/1.73 m2) 87.1 (17.2) -0.03 (-0.08, 0.01) -0.14% (-0.32, 0.04) 
High sensitivity CRP 1.25 (0.69-2.37) -0.27 (-0.31, -0.23)*** -1.10% (-1.26, -0.94)*** 
 
BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration rate; 
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; peO2p, peak exercise oxygen pulse; SD, standard deviation; SBP, systolic 
blood pressure; a , Partial correlation coefficients between relative peO2p and the row variables;. 
b , Absolute change in values of relative peO2p per 
1-SD increase in the row variable (or for categorical variables, the absolute difference in mean values of relative peO2p for the category versus the 
reference) adjusted for age; asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001 
  
  
 
Table 2. Associations of relative peak exercise oxygen pulse with sudden cardiac death, fatal coronary heart disease, fatal cardiovascular disease, 
and all-cause mortality  
 
Models 
Relative peak oxygen pulse 
(ml/beats/kg) 
Sudden 
cardiac death 
 Fatal coronary 
heart disease 
 Fatal 
cardiovascular 
disease 
 All-cause 
mortality 
 
 220 cases  336 cases  505 cases  1,097 cases  
 Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value 
Model         
Per 1 SD increase 0.63 (0.54-0.73) < 0.001 0.63 (0.56-0.71) < 0.001 0.66 (0.60-0.73) < 0.001 0.73 (0.68-0.78) < 0.001 
Quartile 1 (6.4-16.8) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (16.8-19.3) 0.62 (0.44-0.87) 0.005 0.65 (0.50-0.86) 0.002 0.65 (0.52-0.81) < 0.001 0.70 (0.60-0.82) < 0.001 
Quartile 3 (19.3-21.9) 0.47 (0.32-0.68) < 0.001 0.43 (0.32-0.59) < 0.001 0.47 (0.37-0.60) < 0.001 0.60 (0.51-0.71) < 0.001 
Quartile 4 (21.9-42.7) 0.35 (0.24-0.53) < 0.001 0.39 (0.28-0.53) < 0.001 0.42 (0.33-0.54) < 0.001 0.49 (0.41-0.58) < 0.001 
Model 2         
Per 1 SD increase 0.77 (0.66-0.90) 0.001 0.76 (0.67-0.86) < 0.001 0.77 (0.69-0.85) < 0.001 0.79 (0.74-0.85) < 0.001 
Quartile 1 (6.4-16.8) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (16.8-19.3) 0.71 (0.51-1.01) 0.054 0.75 (0.57-0.99) 0.041 0.72 (0.58-0.91) 0.005 0.74 (0.63-0.86) < 0.001 
Quartile 3 (19.3-21.9) 0.63 (0.44-0.92) 0.016 0.57 (0.42-0.79) 0.001 0.60 (0.46-0.77) < 0.001 0.69 (0.59-0.82) < 0.001 
Quartile 4 (21.9-42.7) 0.55 (0.36-0.83) 0.005 0.58 (0.42-0.81) 0.001 0.60 (0.46-0.79)  < 0.001 0.59 (0.49-0.70) < 0.001 
Model 3         
Per 1 SD increase 0.76 (0.65-0.89) 0.001 0.75 (0.66-0.86) < 0.001 0.77 (0.70-0.86) < 0.001 0.80 (0.74-0.86) < 0.001 
Quartile 1 (6.4-16.8) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (16.8-19.3) 0.73 (0.52-1.02) 0.067 0.76 (0.58-1.00) 0.047 0.74 (0.59-0.93) 0.009 0.76 (0.65-0.89) 0.001 
Quartile 3 (19.3-21.9) 0.63 (0.43-0.92) 0.016 0.57 (0.42-0.78) < 0.001 0.60 (0.47-0.77) < 0.001 0.70 (0.60-0.83) < 0.001 
Quartile 4 (21.9-42.7) 0.54 (0.36-0.82) 0.004 0.57 (0.41-0.80) 0.001 0.61 (0.47-0.80) < 0.001 0.61 (0.51-0.73) < 0.001 
 
Model 1: adjusted for age 
Model 2: Model 1 plus systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking status, alcohol consumption, prevalent coronary heart disease, 
history of diabetes mellitus, and physical activity 
Model 3: Model 2 plus high sensitivity C-reactive protein and use of beta-blockers 
  
 
 
Figure Titles and Legends 
 
Figure 1. Hazard ratios for sudden cardiac death, fatal coronary heart disease, fatal cardiovascular 
disease, and all-cause mortality by quartiles of relative peak exercise oxygen pulse 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, total cholesterol, high-
density lipoprotein cholesterol, smoking status, alcohol consumption, prevalent coronary heart disease, 
history of diabetes mellitus, and physical activity 
 
  
Figure 2. Hazard ratios per one standard deviation change (4.1 mL per beat-1·kg-1·102) in relative peak 
exercise oxygen pulse for sudden cardiac death and fatal coronary heart disease by several participant 
characteristics 
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Hazard ratios were adjusted for age, systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, smoking status, alcohol consumption, prevalent coronary heart disease, history of diabetes 
mellitus, and physical activity; CHD, coronary heart disease; CI, confidence interval; HDL, high-density 
lipoprotein; HR, hazard ratio; peO2p, peak exercise oxygen pulse; SD, standard deviation; *, p-value for 
interaction; cut-offs for age, body mass index, systolic blood pressure, total cholesterol, and HDL 
cholesterol are based on median values. 
  
Figure 3. Hazard ratios per one standard deviation change (4.1 mL per beat-1·kg-1·102) in relative peak 
exercise oxygen pulse for cardiovascular and all-cause mortality by several participant characteristics 
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Hazard ratios were adjusted for age, systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, smoking status, alcohol consumption, prevalent coronary heart disease, history of diabetes 
mellitus, and physical activity; CHD, coronary heart disease; CI, confidence interval; HDL, high-density 
lipoprotein; HR, hazard ratio; peO2p, peak exercise oxygen pulse; SD, standard deviation; *, p-value for 
interaction; cut-offs for age, body mass index, systolic blood pressure, total cholesterol, and HDL 
cholesterol are based on median values. 
 
 
 
